Objective: The primary aim of our prospective study was to evaluate the usefulness of dual-phase 18F-fluoro-deoxy-glucose PET/computed tomography (18F-FDG PET/CT) in the characterization of pancreatic masses. The secondary aim was to assess whether delayed imaging revealed any prognostic information.
Materials and methods: Fifty patients with periampullary or pancreatic masses on conventional imaging were included in this study. Early and delayed PET/CT was performed, followed by pathological examination in all patients. PET/CT parameters including uptake pattern, SUVearly, SUVdelayed, lesion to background ratio (L/B), and retention index (RI) were assessed for their ability to differentiate benign from malignant lesions. Patients with malignant lesions were followed up for a median duration of 26 months. The association of 11 variables with survival was analyzed by univariate and multivariate methods.
Results: Thirty-one patients had malignant lesions and 19 had benign lesions. The mean SUVearly, L/B, SUVdelayed, and RI between the malignant and benign lesions were statistically significant. The 18F-FDG uptake pattern of the lesions had higher sensitivity (93.5%) and specificity (100%) compared with RI (cutoff 25.7%) (84 and 37%, respectively) for diagnosing malignancy (P<0.05). In univariate analysis both RI (>18.7%) and tumor size (>2.6 cm) predicted significantly poor survival, whereas in multivariate analysis RI (P=0.04) was the only predictor of poor survival.
Conclusion: Dual-phase 18F-FDG PET/CT is not useful in characterizing pancreatic masses as it cannot differentiate benign from malignant lesions, and focal uptake on early PET imaging is the best indicator of malignancy. A possible benefit in performing a delayed scan is that a high RI (>18.7) can predict poor survival and hence may be useful in treatment planning.
Departments of aNuclear Medicine & PET
cCytology & Gynaecological Pathology
eGeneral Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Correspondence to Bhagwant R. Mittal, MD, Department of Nuclear Medicine & PET, Postgraduate Institute of Medical Education and Research, Chandigarh 160 012, India Tel: +91 172 2756722; fax: +91 172 2742858; e-mail: email@example.com
Received January 15, 2014
Accepted May 23, 2014